GW Pharmaceuticals PLC- (NASDAQ:GWPH) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, BidAskClub reports.
Other analysts have also recently issued reports about the company. JPMorgan Chase & Co. assumed coverage on GW Pharmaceuticals PLC- in a research report on Thursday, January 2nd. They set an “overweight” rating and a $134.00 price target for the company. Evercore ISI reiterated a “buy” rating on shares of GW Pharmaceuticals PLC- in a research report on Monday, November 11th. Cantor Fitzgerald reiterated an “overweight” rating and set a $174.00 price target on shares of GW Pharmaceuticals PLC- in a research report on Wednesday, November 6th. Bank of America reiterated a “buy” rating and set a $218.00 price target on shares of GW Pharmaceuticals PLC- in a research report on Wednesday, September 25th. Finally, HC Wainwright reiterated a “buy” rating and set a $170.00 price target on shares of GW Pharmaceuticals PLC- in a research report on Wednesday, December 18th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $191.82.
GW Pharmaceuticals PLC- stock traded up $2.48 during midday trading on Tuesday, reaching $119.49. The company had a trading volume of 257,754 shares, compared to its average volume of 487,836. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.33 and a quick ratio of 6.60. GW Pharmaceuticals PLC- has a 12-month low of $95.71 and a 12-month high of $196.00. The company has a market capitalization of $3.66 billion, a P/E ratio of -11.31 and a beta of 2.13. The firm’s fifty day simple moving average is $104.68 and its 200-day simple moving average is $130.75.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.39. The business had revenue of $90.97 million during the quarter, compared to analysts’ expectations of $86.84 million. GW Pharmaceuticals PLC- had a negative return on equity of 23.04% and a negative net margin of 26.80%. On average, analysts expect that GW Pharmaceuticals PLC- will post -3.5 EPS for the current fiscal year.
In other GW Pharmaceuticals PLC- news, Chairman Geoffrey W. Dr Guy sold 420,000 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $108.41, for a total transaction of $45,532,200.00. Also, Director Cabot Brown sold 3,576 shares of the business’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $8.58, for a total value of $30,682.08. Following the transaction, the director now directly owns 20,232 shares in the company, valued at approximately $173,590.56. The disclosure for this sale can be found here. Insiders have sold 428,916 shares of company stock worth $45,611,850 in the last three months. 3.60% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Independent Investors Inc. acquired a new position in GW Pharmaceuticals PLC- during the fourth quarter worth $1,045,000. Nomura Holdings Inc. purchased a new stake in GW Pharmaceuticals PLC- during the third quarter worth about $5,005,000. Voloridge Investment Management LLC increased its stake in GW Pharmaceuticals PLC- by 630.2% during the third quarter. Voloridge Investment Management LLC now owns 18,430 shares of the biopharmaceutical company’s stock worth $2,120,000 after purchasing an additional 15,906 shares during the period. Wildcat Capital Management LLC purchased a new stake in GW Pharmaceuticals PLC- during the third quarter worth about $805,000. Finally, Public Employees Retirement System of Ohio increased its stake in shares of GW Pharmaceuticals PLC- by 51.9% during the third quarter. Public Employees Retirement System of Ohio now owns 10,423 shares of the biopharmaceutical company’s stock worth $1,199,000 after buying an additional 3,559 shares during the period. 81.09% of the stock is currently owned by institutional investors.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Recommended Story: How can investors invest in the S&P/TSX Index?
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.